Celiac disease Medical Services in China

Celiac disease is a chronic, immune-mediated systemic disorder triggered by dietary gluten and related prolamins in genetically susceptible individuals. It primarily affects the small intestine, causing villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis—hallmarks of gluten-induced enteropathy. Pathogenesis involves a complex interplay of genetic, environmental, and immunologic factors: over 95% of patients carry HLA-DQ2 or HLA-DQ8 haplotypes, which present deamidated gliadin peptides to CD4+ T cells, initiating an adaptive immune response. Concurrently, tissue transglutaminase (tTG) autoantibodies are produced, contributing to mucosal damage and extraintestinal manifestations. Non-HLA genes (e.g., IL2, SH2B3) further modulate risk. Epidemiologically, celiac disease affects approximately 1% of the global population, though prevalence varies regionally—ranging from 0.3% to 2.6%—and remains significantly underdiagnosed in China, where seroprevalence studies suggest ~0.4–0.7% in general populations and higher rates (up to 2.3%) in high-risk groups such as first-degree relatives or patients with type 1 diabetes or autoimmune thyroiditis. Key risk factors include family history (10–20% risk among first-degree relatives), HLA genotype, early infant feeding practices (e.g., timing of gluten introduction), gastrointestinal infections (e.g., recurrent rotavirus), and comorbid autoimmune conditions. Untreated celiac disease leads to malabsorption of micronutrients (iron, folate, vitamin D, B12), osteoporosis, infertility, neurological complications (e.g., gluten ataxia, peripheral neuropathy), and a 2–4-fold increased risk of non-Hodgkin lymphoma and small bowel adenocarcinoma. Quality of life is profoundly impacted: patients report persistent fatigue, abdominal pain, bloating, diarrhea or constipation, anxiety, depression, social isolation due to dietary restrictions, and reduced work productivity. Even asymptomatic or 'silent' cases show histologic damage and elevated long-term morbidity risks. Diagnosis requires serologic testing (IgA anti-tissue transglutaminase, IgA endomysial antibodies) followed by confirmatory duodenal biopsy while on a gluten-containing diet. Genetic testing for HLA-DQ2/DQ8 is useful for ruling out disease when serology is equivocal. Lifelong strict adherence to a gluten-free diet (GFD) remains the only evidence-based treatment—eliminating wheat, barley, rye, and contaminated oats. Nutritional counseling, regular monitoring of serologic response and bone mineral density, and screening for associated autoimmune disorders are essential components of comprehensive care. Patient education, access to certified gluten-free foods, and psychosocial support significantly improve long-term outcomes and quality of life.

Celiac disease is a chronic, immune-mediated systemic disorder triggered by the ingestion of gluten and related prolamins in genetically susceptible individuals. It is not an allergy nor a simple intolerance but a T-cell–driven autoimmune condition characterized by inflammation and villous atrophy in the proximal small intestine, with potential extraintestinal manifestations affecting multiple organ systems. The primary cause is exposure to dietary gluten—a complex mixture of storage proteins (gliadins and glutenins) found in wheat, barley, and rye. Upon ingestion, gluten-derived peptides—particularly the 33-mer fragment of α2-gliadin—are deamidated by tissue transglutaminase 2 (tTG2), an enzyme highly expressed in the intestinal mucosa. This post-translational modification enhances the binding affinity of these peptides to HLA-DQ2 or HLA-DQ8 molecules on antigen-presenting cells, leading to activation of CD4+ T lymphocytes. This cascade initiates a robust adaptive immune response, resulting in cytokine release (e.g., interferon-γ, IL-21), B-cell differentiation into autoantibody-producing plasma cells (yielding anti-tTG, anti-endomysial, and anti-deamidated gliadin peptide antibodies), and cytotoxic intraepithelial lymphocyte activity that damages enterocytes and disrupts intestinal architecture.

Genetic susceptibility is essential and non-redundant: over 95% of patients carry HLA-DQ2.5 (encoded by *DQA1*05:01/*DQB1*02:01 heterodimer), ~5% carry HLA-DQ8 (*DQA1*03:01/*DQB1*03:02), and rare cases involve HLA-DQ2.2. However, HLA positivity alone is insufficient—approximately 30–40% of the general population carries these alleles, yet only 1–3% of carriers develop celiac disease. Non-HLA genetic factors contribute significantly, with genome-wide association studies identifying over 40 risk loci outside the major histocompatibility complex. Key contributors include variants in *IL2*, *IL21*, *SH2B3*, *CTLA4*, and *TAGAP*, all involved in T-cell regulation, immune tolerance, and lymphocyte signaling pathways.

Environmental triggers are critical for disease onset and expression. Gluten exposure is the indispensable exogenous trigger; disease does not manifest in its absence. Timing and quantity of gluten introduction during infancy influence risk: early introduction (<4 months) or late introduction (>7 months), particularly when coupled with concurrent infections or breastfeeding cessation, may increase susceptibility. Gastrointestinal infections—especially recurrent rotavirus infection in early childhood—are associated with higher seroconversion rates and subsequent celiac disease development, likely via disruption of epithelial barrier integrity, microbial dysbiosis, and aberrant immune priming. Alterations in the gut microbiome composition (e.g., reduced *Bifidobacterium* spp., increased *Bacteroides vulgatus*) during critical developmental windows may impair oral tolerance induction. Other proposed environmental co-factors include cesarean delivery (altering initial microbial colonization), antibiotic exposure in infancy, and vitamin D deficiency—though evidence remains associative rather than causative.

Established risk factors include both immutable and modifiable elements. First-degree relatives of affected individuals have a 10–15% lifetime risk, reflecting shared genetics and environment. Certain autoimmune conditions confer markedly elevated risk: type 1 diabetes (5–10% prevalence), autoimmune thyroiditis (up to 15%), Sjögren’s syndrome, Addison’s disease, and autoimmune liver disorders (e.g., primary biliary cholangitis). Chromosomal disorders substantially increase risk—Down syndrome (5–12%), Turner syndrome (2–5%), and Williams syndrome (up to 25%). Selective IgA deficiency (prevalence ~2.5% in celiac patients vs. 0.2% general population) complicates serologic diagnosis and correlates with more severe mucosal injury. Additional epidemiologic risk factors include female sex (female-to-male ratio ~2:1), northern European ancestry, and socioeconomic status (higher incidence in higher-income populations, possibly reflecting diagnostic ascertainment bias and lifestyle-related environmental exposures). Importantly, while gluten is necessary, its role is permissive—not sufficient—emphasizing the multifactorial interplay among genetic predisposition, immune dysregulation, intestinal barrier dysfunction, and environmental perturbations in disease pathogenesis.

Celiac disease is a chronic, immune-mediated systemic disorder triggered by dietary gluten and related prolamins in genetically susceptible individuals—primarily those carrying HLA-DQ2 or HLA-DQ8 haplotypes. It affects approximately 1% of the global population, with significant underdiagnosis due to its heterogeneous clinical presentation. Symptoms may manifest at any age, from infancy through late adulthood, and range from classic gastrointestinal (GI) manifestations to extraintestinal, subclinical, or silent forms.

Early symptoms—particularly in infants and young children following gluten introduction (typically after 6–12 months of age)—often include failure to thrive, irritability, chronic diarrhea, abdominal distension, muscle wasting, and delayed growth or puberty. Infants may present with pallor, hypotonia, and developmental delay. In toddlers, recurrent abdominal pain, anorexia, and steatorrhea are common precursors to overt malabsorption. Notably, early symptom onset correlates strongly with more severe mucosal injury on biopsy and higher risk of persistent autoimmunity if gluten exposure continues.

Typical symptoms reflect small intestinal mucosal damage and consequent malabsorption. These include chronic, non-bloody diarrhea (often pale, foul-smelling, and greasy), postprandial abdominal bloating and distension, excessive flatulence, and crampy, intermittent abdominal pain. Weight loss despite adequate caloric intake is frequent in adults; in children, it manifests as growth faltering or short stature. Steatorrhea results from impaired fat digestion and absorption due to villous atrophy and reduced brush-border enzyme activity (e.g., lactase, sucrase). Nutrient deficiencies—including iron-deficiency anemia (often refractory to oral iron), folate and vitamin B12 deficiency (contributing to macrocytic anemia and peripheral neuropathy), and deficiencies in fat-soluble vitamins (A, D, E, K)—are hallmark features. Vitamin D deficiency frequently leads to secondary hyperparathyroidism, osteopenia, or osteoporosis—even in young adults—and may present with bone pain or stress fractures.

Accompanying symptoms reflect systemic immune activation and extra-intestinal involvement. Dermatitis herpetiformis—a pruritic, symmetric, papulovesicular rash on extensor surfaces (elbows, knees, buttocks, scalp)—occurs in ~15–25% of patients and is pathognomonic for celiac disease, sharing identical serologic and genetic markers. Neurological manifestations include gluten ataxia (gait instability, dysarthria, nystagmus), peripheral neuropathy (sensory > motor), migraine, and, less commonly, epilepsy with occipital calcifications. Psychiatric comorbidities such as depression, anxiety, and fatigue are highly prevalent and may precede GI symptoms. Reproductive disturbances include unexplained infertility, recurrent miscarriage, and amenorrhea. Dental enamel hypoplasia—especially in permanent teeth—reflects childhood-onset disease. Elevated liver enzymes (mild transaminitis) occur in up to 40% of newly diagnosed cases and typically normalize on a gluten-free diet. Arthralgias, arthropathies (e.g., sacroiliitis), and autoimmune thyroiditis (Hashimoto’s or Graves’ disease) are also common associations.

Complications arise from persistent gluten exposure and chronic inflammation. Refractory celiac disease (RCD)—defined as persistent or recurrent malabsorptive symptoms and villous atrophy despite strict gluten-free diet for ≥12 months—is classified into Type I (clonal intraepithelial lymphocytes, normal immunophenotype) and Type II (aberrant lymphocyte phenotype, high risk of enteropathy-associated T-cell lymphoma [EATL]). EATL is a rare but aggressive malignancy with poor prognosis; its incidence is 60–100-fold higher in celiac disease than in the general population. Other malignancies with elevated risk include small bowel adenocarcinoma and oropharyngeal/esophageal squamous cell carcinoma. Long-standing untreated disease predisposes to ulcerative jejunoileitis, collagenous sprue, and hyposplenism (increasing susceptibility to encapsulated bacterial infections). Metabolic bone disease—including osteoporosis-related vertebral compression fractures—remains a leading cause of morbidity. Additionally, patients face increased risk of other autoimmune disorders: type 1 diabetes mellitus (prevalence ~5–10%), autoimmune hepatitis, primary biliary cholangitis, and Sjögren syndrome.

Diagnosis requires a stepwise approach. Serologic testing is first-line: tissue transglutaminase IgA (tTG-IgA) is the most sensitive (>95%) and specific (>95%) assay; total serum IgA must be measured concurrently to exclude IgA deficiency (present in ~2–3% of celiac patients), which may yield false-negative tTG-IgA. In IgA-deficient individuals, deamidated gliadin peptide (DGP) IgG or tTG-IgG is recommended. Endoscopic duodenal biopsy remains the diagnostic gold standard: at least four biopsies (including from the bulb) should be obtained to assess for characteristic histopathology—villous atrophy (partial or total), crypt hyperplasia, intraepithelial lymphocytosis (>25 lymphocytes/100 epithelial cells), and basal plasmacytosis. Marsh-Oberhuber classification (Types 1–4) guides histologic grading, though diagnosis does not require full-blown villous atrophy (Marsh 3); Marsh 1–2 changes with positive serology and clinical response to gluten withdrawal support diagnosis. Genetic testing for HLA-DQ2/DQ8 has high negative predictive value (99% sensitivity); absence effectively excludes celiac disease but presence alone is insufficient for diagnosis (as ~30–40% of the general population carries these alleles).

Differential diagnosis is critical given overlapping presentations. Irritable bowel syndrome (IBS) shares abdominal pain, bloating, and altered bowel habits—but lacks serologic markers, histologic injury, or nutritional deficiencies. Non-celiac gluten sensitivity (NCGS) presents with similar symptoms but negative celiac serology and histology, and no HLA-DQ2/DQ8 association; diagnosis is one of exclusion after ruling out celiac disease and wheat allergy. Tropical sprue—endemic in certain regions—features malabsorption and megaloblastic anemia but responds to antibiotics and folic acid, and shows distinct histologic features (e.g., foamy macrophages). Small intestinal bacterial overgrowth (SIBO) causes bloating and diarrhea but is confirmed via breath testing and resolves with antimicrobials. Crohn’s disease may mimic celiac disease clinically and endoscopically but demonstrates transmural inflammation, granulomas, and skip lesions; serologic markers (ASCA, anti-CBir1) aid distinction. Lactose intolerance causes transient diarrhea and bloating post-dairy ingestion but lacks systemic features or mucosal damage. Finally, giardiasis and other parasitic infections can induce villous blunting and must be excluded via stool ova-and-parasite studies and PCR assays. Accurate diagnosis hinges on maintaining gluten consumption (≥2 servings daily for ≥6 weeks) prior to serologic testing and biopsy to avoid false-negative results.

Celiac disease is a chronic, immune-mediated enteropathy triggered by dietary gluten in genetically susceptible individuals—primarily those carrying HLA-DQ2 or HLA-DQ8 haplotypes. It affects approximately 1% of the global population and is characterized by heterogeneous clinical manifestations ranging from classic gastrointestinal symptoms (e.g., chronic diarrhea, steatorrhea, abdominal distension, weight loss) to extraintestinal manifestations (e.g., iron-deficiency anemia, osteoporosis, dermatitis herpetiformis, elevated transaminases, infertility, and neurological deficits). Diagnosis requires serologic testing (tissue transglutaminase IgA antibodies [tTG-IgA], deamidated gliadin peptide antibodies [DGP-IgA/IgG], and total serum IgA to rule out deficiency), followed by confirmatory duodenal biopsy demonstrating characteristic histopathological changes—including intraepithelial lymphocytosis, crypt hyperplasia, and villous atrophy—per the Modified Marsh Classification. Genetic testing for HLA-DQ2/DQ8 serves as a useful negative predictive tool but is not diagnostic on its own.

Conservative treatment remains the cornerstone of celiac disease management and is universally recommended as lifelong, strict gluten avoidance. Gluten is a storage protein found in wheat, barley, rye, and their derivatives; even trace exposure (as little as 10–50 mg daily) can provoke mucosal inflammation and symptom recurrence. Patients must eliminate all sources of gluten—including hidden sources in medications, supplements, cosmetics, and processed foods (e.g., soy sauce, malt vinegar, modified food starch, hydrolyzed vegetable protein). Comprehensive nutritional counseling by a registered dietitian experienced in celiac disease is essential to ensure dietary adequacy, prevent micronutrient deficiencies (especially iron, folate, vitamin B12, vitamin D, calcium, and zinc), and support long-term adherence. Education extends to label reading, cross-contamination prevention (e.g., dedicated kitchen utensils, separate toasters), dining-out strategies, and travel planning. Regular follow-up includes symptom assessment, serologic monitoring (tTG-IgA every 6–12 months initially, then annually if stable), and periodic evaluation of nutritional status and bone mineral density. In refractory cases, repeat endoscopy with biopsy may be warranted to assess mucosal healing and exclude complications such as ulcerative jejunoileitis or enteropathy-associated T-cell lymphoma (EATL).

Pharmacologic therapy has no established role in routine celiac disease management. No drug is currently approved by major regulatory agencies (FDA, EMA, NMPA) for induction or maintenance of remission. Several agents are under active investigation: larazotide acetate (a zonulin inhibitor that reduces intestinal permeability), latiglutenase (a gluten-specific protease), and Nexvax2 (a therapeutic vaccine targeting gluten-reactive T cells). However, none have demonstrated sufficient efficacy or safety for clinical adoption outside controlled trials. Corticosteroids or immunosuppressants (e.g., azathioprine, budesonide) may be considered only in rare, biopsy-confirmed refractory celiac disease (RCD) types I or II—particularly when persistent villous atrophy and malabsorption persist despite rigorous gluten-free diet (GFD) adherence and exclusion of inadvertent gluten exposure. RCD type II carries a significantly increased risk of clonal T-cell lymphoproliferation and warrants referral to specialized centers for flow cytometry, T-cell receptor gene rearrangement studies, and surveillance imaging.

Surgical intervention is not indicated for uncomplicated celiac disease. Surgery may become necessary only in the context of severe complications, including stricturing or perforating complications of refractory disease, massive gastrointestinal bleeding unresponsive to medical therapy, or development of malignancy (e.g., EATL, small bowel adenocarcinoma). In such cases, resection of affected bowel segments may be performed, though outcomes remain guarded due to underlying immune dysregulation and high postoperative morbidity. Laparoscopic approaches are preferred when feasible, and multidisciplinary oncology input is mandatory for malignancy-related surgery. Importantly, surgical intervention does not obviate the need for lifelong GFD nor mitigate autoimmune comorbidities.

Treatment advantages in China include rapidly expanding access to high-quality, domestically manufactured gluten-free products—many certified by the China Celiac Disease Alliance and compliant with national standards (GB/T 23780–2022, which defines gluten content <20 ppm as 'gluten-free'). Major tertiary hospitals, especially those affiliated with universities (e.g., Peking Union Medical College Hospital, West China Hospital, Zhongshan Hospital), offer integrated care pathways combining gastroenterology, nutrition, pathology, and genetics. Endoscopic services feature high-resolution magnifying chromoendoscopy and rapid on-site cytopathology evaluation, facilitating precise biopsy targeting. Moreover, China’s national health insurance system increasingly covers serologic testing (tTG-IgA, DGP) and upper endoscopy for confirmed indications, reducing financial barriers. Telemedicine platforms enable longitudinal dietary coaching and remote symptom tracking, particularly beneficial for patients in rural regions. Research initiatives—including large-scale cohort studies like the China Celiac Registry—are generating region-specific epidemiologic and phenotypic data, informing culturally adapted dietary guidelines (e.g., gluten-free alternatives using rice, buckwheat, and millet flours) and improving diagnostic awareness among primary care providers.

Recovery advice emphasizes patience and precision: mucosal healing typically begins within weeks of strict GFD initiation but may require 12–24 months for full histologic normalization in adults—longer in older patients or those with longstanding disease. Symptom improvement often precedes histologic recovery; therefore, clinical response alone should not be used to gauge dietary compliance. Patients should avoid oats unless labeled 'pure, gluten-free' (due to frequent cross-contamination), and reintroduce dairy cautiously if lactose intolerance coexists (usually transient). Routine supplementation—especially vitamin D (800–2000 IU/day), calcium (1000–1200 mg/day), and iron (if ferritin <30 ng/mL)—should be individualized based on baseline labs and follow-up trends. Annual screening for associated autoimmune conditions (e.g., thyroid function tests, type 1 diabetes autoantibodies) is advised. Psychological support is integral: up to 30% of patients report anxiety or depression related to dietary burden and social isolation; cognitive-behavioral therapy and peer-led support groups (including online communities moderated by Chinese gastroenterologists) improve quality of life and adherence. Finally, women of childbearing age should optimize nutritional status preconception, as untreated celiac disease increases risks of miscarriage, intrauterine growth restriction, and preterm birth. With sustained adherence, most patients achieve full functional recovery, normal life expectancy, and reduced risk of long-term complications.